Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Gao, Yong Hua ^a   Guan, Wei Jie ^a   Xu, Gang ^a   Tang, Yan ^a   Gao, Yang ^a   Lin, Zhi Ya ^a   Lin, Zhi Min ^a   Zhong, Nan Shan ^a   Chen, Rong Chang ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; MACROLIDE; ROXITHROMYCIN;

ABDOMINAL DISCOMFORT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; CHILD; COMMON COLD; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEARING IMPAIRMENT; HEART PALPITATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NON CYSTIC FIBROSIS BRONCHIECTASIS; PRURITUS; QT PROLONGATION; QUALITY CONTROL; QUALITY OF LIFE; RASH; RESPIROMETRY; SINUSITIS; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT DURATION; CHEMICALLY INDUCED; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; BRONCHIECTASIS; CHILD; DIARRHEA; HUMANS; MACROLIDES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84897445839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090047     Document Type: Article

References (35)

1. Pasteur MC, Bilton D, Hill AT (2010) British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65 Suppl 1: i1-58.
2. De Soyza A, Brown JS, Loebinger MR (2013) Research priorities in bronchiectasis. Thorax 68: 695-696.
3. Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T, et al. (2013) Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS ONE 8: e71109.
4. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, et al. (2010) Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 138: 944-949.
5. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R (2012) Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 142: 432-439.
6. Twiss J, Metcalfe R, Edwards E, Byrnes C (2005) New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 90: 737-740. (Pubitemid 40922509)
7. Saynajakangas O, Keistinen T, Tuuponen T, Kivela SL (1997) Bronchiectasis in Finland: trends in hospital treatment. Respir Med 91: 395-398. (Pubitemid 27308190)
8. Cai Y, Chai D, Wang R, Bai N, Liang BB, et al. (2011) Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 66: 968-978.
9. Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, et al. (2013) Macrolides for the long-term management of asthma - a meta-analysis of randomized clinical trials. Allergy 68: 1040-1049.
10. Spagnolo P, Fabbri LM, Bush A (2013) Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 42: 239-251.
11. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157: 1829-1832.
12. Benden C, Boehler A (2009) Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 87: 1538-1540.
13. Yao GY, Ma YL, Zhang MQ, Gao ZC (2013) Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis. Respiration Doi: 10.1159/000350828 (Article in press).
14. Kanoh S, Rubin BK (2010) Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 23: 590-615.
15. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, et al. (2013) Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 309 (12). 1260-1267.
16. Altenburg J, Graaff CS, Stienstra Y, Sloos JH, Haren EH, et al. (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309 (12). 1251-1259.
17. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, et al. (2012) Azithromycin for prevention of exacerbations in non-cystic fi brosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. The Lancet 380: 660-667.
18. Evans DJ, Bara AI, Greenstone M (2007) Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev: CD001392.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
20. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
21. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH (1997) Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 10(5). 994-999. (Pubitemid 27201800)
22. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, et al. (1999) A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13: 361-364. (Pubitemid 29086834)
23. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, et al. (2005) The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 4: 117-122. (Pubitemid 40613959)
24. Masekela R, Anderson R, Gongxeka H, Steel HC, Becker PJ, et al. (2013) Lack of efficacy of an immunomodulatory macrolide in childhood HIV related bronchiectasis: A randomised, placebo-controlled trial. J Antivir Antiretrovir 5: 044-049.
25. de Diego A, Milara J, Martinez E, Palop M, Leon M, et al. (2013) Effects of Long-term Azithromycin Therapy on Airway Oxidative Stress Markers in non-Cystic Fibrosis bronchiectasis. Respirology Doi: 10.1111/resp.12130. (Article in press).
26. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, et al. (2013) Longterm azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 1: 610-620.
27. Poletti V, Casoni G, Chilosi M, Zompatori M (2006) Diffuse panbronchiolitis. Eur Respir J 28: 862-871. (Pubitemid 46332008)
28. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, et al. (2012) Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 186: 657-665.
29. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, et al. (2004) Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 400-407. (Pubitemid 39214614)
30. Jones PW (2005) St. George's Respiratory Questionnaire: MCID. COPD 2: 75-79.
31. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J (2007) Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132: 1565-1572. (Pubitemid 350156014)
32. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R (1997) Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 156: 536-541. (Pubitemid 27351991)
33. Serisier DJ (2013) Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 1: 262-274.
34. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366: 1881-1890.
35. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, et al. (2013) Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 346: f1235.